American Heart Association 2015 Scientific Sessions
The AHA Scientific Sessions will cover "the most timely and significant advances in basic, clinical, translational and population health research, spanning the full spectrum of cardiovascular disease from a variety of perspectives, from prevention, through diagnosis and through treatment."
Q&A With Christopher Sun From University of Toronto: Automated External Defibrillators Only As Good As Ability to Reach Them
Q&A With Matthew G. Nayor From Brigham & Women's Hospital: Framingham Heart Study Looks At Impact of Carbon Monoxide
Analysis of data from the PEGASUS-TIMI 54 trial showed high rates of treatment discontinuation due to adverse events such as bleeding and dyspnea, with the highest rate occurring in the first year of treatment. Patients who stuck with treatment experienced a reduction in cardiovascular death, myocardial infarction, and stroke.
Q&A With Maria Chiu From the University of Toronto: Local Walkability Key Factor In Helping Keep People Healthy
Q&A With Michelle Wong From Johns Hopkins University: Planting Seeds For Healthy Living Through School Gardens
The scoring system known as CHA2DS2-VASc is commonly used as a clinical guideline for assessing ischemic stroke risk in patients with atrial fibrillation (AF). A research team from Santiago, Chile found it can also predict vascular dysfunction and cardiovascular events in high-risk patients who do not have AF.
A new tool for assessing the risk of thromboembolic events in patients with atrial fibrillation performed better than the existing standard in a large retrospective analysis. ATRIA risk scores were less likely than CHA2DS2-VASc scores to mistakenly characterize patients as "high risk" and, therefore, to lead to the overuse of anticoagulation.